TABLE 1.
Comparison of epidemiologic, laboratory, biologic and molecular characteristics in patients with CMML stratified by age younger than 60 years vs 60‐79 years vs 80 years or older
| Variables |
All patients N = 518 |
Patients <60 years N = 57 |
Patients 60‐79 years N = 357 |
Patients ≥80 years N = 104 |
P Value |
|---|---|---|---|---|---|
| Median OS (months) | 27.6 | 21.1 | 29.4 | 27.0 | |
| Epidemiologic variables | |||||
|
Age in years Median (range) |
72 (34‐96) | 54 (34‐59) | 71 (60‐80) | 83 (80‐96) | |
|
Sex (male) N (%) |
329 (64%) | 36 (63%) | 232 (65%) | 61 (59%) | .4004 |
| Laboratory variables | |||||
|
WBC × 109/L Median (range) |
11.8 (0.7‐271) | 12.8 (2.1‐116.5) | 11.3 (0.7‐271) | 12.7 (1.6‐156) | .980 |
|
Hb g/dL Median (range) |
11.0 (4.3‐16.5) | 11.1 (6.0‐16.1) | 11.1 (4.3‐16.5) | 10.5 (5.1‐14.9) | .089 |
|
PLT × 109/L Median (range) |
108 (2‐1181) | 105 (2‐510) | 109 (5‐1181) | 103 (6‐ 867) | .427 |
|
PB Mono % Median (range) |
22 (0‐77) | 22 (3‐50) | 22 (0‐74) | 24 (5‐77) | .295 |
|
PB Blast % Median (range) |
0 (0‐19) | 1 (0‐17) | 0 (0‐18) | 0 (0‐19) | .008 |
| Proportion of patients with PB blasts (%) | 34% | 59.6% | 31.8% | 29.1% | .0035 |
|
LDH IU/mL Median (range) |
256 (67‐3380) | 277 (120‐1952) | 255 (68‐3380) | 258 (67‐1058) | .275 |
| Biologic variable | |||||
| Spont. CFU‐GM/105 PBMNC | 6 (0‐1127) | 21.5 (0‐762) | 5.5 (0‐1127) | 7.0 (0‐812) | .931 |
| Mutated genesa | Positive cases/total number of cases (proportion in %) | ||||
| NRAS | 34/222 (15%) | 1/17 (6%) | 26/153 (17%) | 7/52 (13%) | .8934 |
| KRAS | 20/221 (9%) | 0/17 (0%) | 16/152 (10.5%) | 4/52 (7.7%) | .7937 |
| NF1 | 15/196 (7.7%) | 1/14 (7.1%) | 10/136 (7.4%) | 4/46 (8.7%) | .7739 |
| CBL | 21/222 (9.5%) | 2/17 (11.8%) | 12/153 (7.8%) | 7/52 (13.5%) | .4287 |
| PTPN11 | 12/223 (5.4%) | 2/17 (11.8%) | 7/153 (4.6%) | 3/53 (5.7%) | .6636 |
| JAK2 V617F | 34/263 (12.9%) | 4/22 (18.2%) | 28/184 (15.2%) | 2/57 (3.5%) | .0214 |
| SETBP1 | 47/220 (21.4%) | 5/17 (29.4%) | 29/151 (19.2%) | 13/52 (25%) | .8069 |
| TET2 | 149/221 (67,4%) | 9/17 (53%) | 104/152 (68.4%) | 36/52 (69.2%) | .4014 |
| DNMT3A | 17/222 (7.7%) | 1/17 (5.9%) | 9/153 (5.9%) | 7/52 13.5%) | .105 |
| EZH2 | 35/221 (15.8%) | 1/16 (6.2%) | 25/153 (16.3%) | 9/52 (17.3%) | .4589 |
| ASXL1 | 54/222 (24.3%) | 5/17 (29.4%) | 37/153 (24.2%) | 12/52 (23.1%) | .6746 |
| IDH1/2 | 11/220 (5%) | 1/17 (5.9%) | 9/151 (6.0%) | 1/52 (1.9%) | .2963 |
| SRSF2 | 43/221 (19.5%) | 1/17 (5.9%) | 31/152 (20.4%) | 11/52 (21.2%) | .3516 |
| U2AF1 | 14/221 (6.3%) | 0/17 (0%) | 12/153 (7.8%) | 2/51 (3.9%) | .8561 |
| SF3B1 | 12/221 (5.4%) | 2/17 (11.8%) | 8/153 (5.2%) | 2/51 (3.9%) | .3296 |
| ZRSR2 | 15/222 (6.8%) | 1/17 (5.9%) | 11/153 (7.2%) | 3/52 (5.8%) | .8375 |
| RUNX1 | 19/222 (8.6%) | 1/17 (5.9%) | 13/153 (8.5%) | 5/52 (9.6%) | .6621 |
| TP53 | 7/204 (3.4%) | 0/16 (0%) | 5/139 (3.6%) | 2/49 (4.1%) | .5637 |
| Cytogenetics | |||||
| High risk | 52/274 (19%) | 12/38 (31.6%) | 28/185 (15.1%) | 12/51 (23.5%) | .5408 |
Abbreviations: CFU‐GM, colony‐forming unit‐granulocyte‐macrophage; CMML, chronic myelomonocytic leukaemia; Cytogenetic Risk, high‐risk cytogenetic including trisomy 8, complex karyotype (≥3 abnormalities) and abnormalities of chromosome 7; Hb, haemoglobin; LDH, lactate dehydrogenase; MNC, mononuclear cells; PB, peripheral blood; PLT, platelet count; WBC, white blood cell count.
Significant values are bold.
At least 5% VAF.